...
首页> 外文期刊>Frontiers in Molecular Neuroscience >Expression and Regulatory Network Analysis of miR-140-3p, a New Potential Serum Biomarker for Autism Spectrum Disorder
【24h】

Expression and Regulatory Network Analysis of miR-140-3p, a New Potential Serum Biomarker for Autism Spectrum Disorder

机译:miR-140-3p的表达和调控网络分析,一种自闭症谱系障碍的新型潜在血清生物标志物

获取原文
           

摘要

Given its prevalence and social impact, Autism Spectrum Disorder (ASD) is drawing much interest. Molecular basis of ASD is heterogeneous and only partially known. Many factors, including disorders comorbid with ASD, like TS (Tourette Syndrome), complicate ASD behavior-based diagnosis and make it vulnerable to bias. To further investigate ASD etiology and to identify potential biomarkers to support its precise diagnosis, we used TaqMan Low Density Array technology to profile serum miRNAs from ASD, TS, and TS+ASD patients, and unaffected controls (NCs). Through validation assays in 30 ASD, 24 TS, and 25 TS+ASD patients and 25 NCs, we demonstrated that miR-140-3p is upregulated in ASD vs.: NC, TS, and TS+ASD (Tukey's test, p-values = 0.03, = 0.01, < 0.0001, respectively). ΔCt values for miR-140-3p and YGTSS (Yale Global Tic Severity Scale) scores are positively correlated (Spearman r = 0.33; Benjamini-Hochberg p = 0.008) and show a linear relationship (p = 0.002). Network functional analysis showed that nodes controlled by miR-140-3p, especially CD38 and NRIP1 which are its validated targets, are involved in processes convergingly dysregulated in ASD, such as synaptic plasticity, immune response, and chromatin binding. Biomarker analysis proved that serum miR-140-3p can discriminate among: (1) ASD and NC (Area under the ROC curve, AUC: 0.70; sensitivity: 63.33%; specificity: 68%); (2) ASD and TS (AUC: 0.72; sensitivity: 66.66%; specificity: 70.83%); (3) ASD and TS+ASD (AUC: 0.78; sensitivity: 73.33%; specificity: 76%). Characterization of miR-140-3p network would contribute to further clarify ASD etiology. Serum miR-140-3p could represent a potential non-invasive biomarker for ASD, easy to test through liquid biopsy.
机译:鉴于其自发性和社会影响,自闭症谱系障碍(ASD)引起了极大的兴趣。 ASD的分子基础是异质的,只有部分已知。许多因素,包括与ASD并存的疾病,如TS(Tourette综合征),使基于行为的ASD诊断变得复杂,并且容易受到偏见的影响。为了进一步研究ASD病因并识别潜在的生物标志物以支持其精确诊断,我们使用了TaqMan低密度阵列技术来分析ASD,TS和TS + ASD患者以及未患病对照(NC)的血清miRNA。通过在30名ASD,24名TS和25名TS + ASD患者以及25名NC中进行的验证试验,我们证明了miR-140-3p在ASD与:NC,TS和TS + ASD中被上调(Tukey检验,p值= 0.03,= 0.01,<0.0001)。 miR-140-3p和YGTSS(耶鲁全球Tic严重量表)得分的ΔCt值呈正相关(Spearman r = 0.33; Benjamini-Hochberg p = 0.008)并显示线性关系(p = 0.002)。网络功能分析表明,受miR-140-3p控制的节点,尤其是CD38和NRIP1是其有效靶点,参与了ASD中聚合失调的过程,例如突触可塑性,免疫应答和染色质结合。生物标志物分析证明血清miR-140-3p可以区分:(1)ASD和NC(ROC曲线下面积,AUC:0.70;灵敏度:63.33%;特异性:68%); (2)ASD和TS(AUC:0.72;敏感性:66.66%;特异性:70.83%); (3)ASD和TS + ASD(AUC:0.78;敏感性:73.33%;特异性:76%)。 miR-140-3p网络的表征将有助于进一步阐明ASD病因。血清miR-140-3p可能代表ASD的潜在非侵入性生物标志物,易于通过液体活检进行检测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号